Thomas Dayspring: Antihypertensive Class and Dementia Risk
Thomas Dayspring, Lipidologist at Early Medical, shared on LinkedIn:
”Thanks to Kellyann Niotis M.D. for alerting me about the largest multinational cohort study conducted to date investigating different classes of antihypertensive drugs and the risk of incident dementia. The conclusion: physicians and patients should consider the reduced risk of all-cause dementia and Vascular Dementia with ARB compared with ACE-I in their risk–benefit assessment.”
Title: Antihypertensive drug classes and risk of incident dementia: a multinational population-based cohort study
Authors: Edmund C L Cheung, Matthew Adesuyan, Máté Szilcz, Lisa M Kalisch Ellett, Sonia Shah, Yogini H Jani, Sara Hägg, Nicole Pratt, Kui Kai Lau, Hao Luo, Eric Yuk Fai Wan, Esther Wai Yin Chan, Ian C K Wong, Jacqueline K Yuen, Kai-Hang Yiu, Robert Howard, Ruth Brauer, Celine S L Chui
Read the full article here.
Stay updated with Hemostasis Today.
-
Dec 16, 2025, 16:14Nicolas Gendron on Sustainability in Anticoagulation and DOACs
-
Dec 16, 2025, 15:39Reza Shojaei: Every Expired Unit of Blood Tells a Story
-
Dec 16, 2025, 14:03Francesco Lo Monaco on Rethinking Blood Pressure: The Major Problem with How We Understand It
-
Dec 16, 2025, 14:03Marilena Vrana Urges EU Policymakers to “Keep Patients at the Centre” of Critical Medicines Act
-
Dec 16, 2025, 14:02Even Distribution of Protective Hemoglobin Prevents Sickle Cell Symptoms
-
Dec 16, 2025, 13:58AHA Awards Shubham Misra Postdoc Grant for LVO Stroke Biomarker Research
-
Dec 16, 2025, 13:00ScholarGPS Ranks Emmanuel J. Favaloro No. 1 in the World for Hemostasis
-
Dec 16, 2025, 11:30Kingsley Wheaton: Sweden is on the Brink of Becoming the World’s 1st Smoke-Free Country
-
Dec 16, 2025, 11:03Matías J Alet on CABOS Project with The Support of WSO